5 results on '"Mottet, N. (Nicolas)"'
Search Results
2. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma
- Author
-
Leenders, G.J.H.L. (Geert), Kwast, Th.H. (Theo) van der, Grignon, D.J., Evans, AJ, Kristiansen, G. (Glen), Kweldam, C.F. (Charlotte), Litjens, G., McKenney, JK, Melamed, J. (Jonathan), Mottet, N. (Nicolas), Paner, G.P., Samaratunga, H, Schoots, I.G. (Ivo), Simko, J.P., Tsuzuki, T., Varma, M, Warren, AY, Wheeler, T.M. (Thomas), Williamson, S.R., Iczkowski, KA, Leenders, G.J.H.L. (Geert), Kwast, Th.H. (Theo) van der, Grignon, D.J., Evans, AJ, Kristiansen, G. (Glen), Kweldam, C.F. (Charlotte), Litjens, G., McKenney, JK, Melamed, J. (Jonathan), Mottet, N. (Nicolas), Paner, G.P., Samaratunga, H, Schoots, I.G. (Ivo), Simko, J.P., Tsuzuki, T., Varma, M, Warren, AY, Wheeler, T.M. (Thomas), Williamson, S.R., and Iczkowski, KA
- Abstract
Five years after the last prostatic carcinoma grading consensus conference of the International Society of Urological Pathology (ISUP), accrual of new data and modification of clinical practice require an update of current pathologic grading guidelines. This manuscript summarizes the proceedings of the ISUP consensus meeting for grading of prostatic carcinoma held in September 2019, in Nice, France. Topics brought to consensus included the following: (1) approaches to reporting of Gleason patterns 4 and 5 quantities, and minor/tertiary patterns, (2) an agreement to report the presence of invasive cribriform carcinoma, (3) an agreement to incorporate intraductal carcinoma into grading, and (4) individual versus aggregate grading of systematic and multiparametric magnetic resonance imaging–targeted biopsies. Finally, developments in the field of artificial intelligence in the grading of prostatic carcinoma and future research perspectives were discussed.
- Published
- 2020
- Full Text
- View/download PDF
3. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma
- Author
-
Leenders, G.J.H.L. (Geert), Kwast, Th.H. (Theo) van der, Grignon, D.J. (David J.), Evans, A.J. (Andrew J.), Kristiansen, G. (Glen), Kweldam, C.F. (Charlotte), Litjens, G. (Geert), McKenney, J.K. (Jesse K.), Melamed, J. (Jonathan), Mottet, N. (Nicolas), Paner, G.P. (Gladell P.), Samaratunga, H. (Hemamali), Schoots, I.G. (Ivo), Simko, J. (Jeff), Tsuzuki, T. (Toyonori), Varma, M. (Murali), Warren, A.Y. (Anne Y.), Wheeler, T.M. (Thomas), Williamson, S.R. (Sean R.), Iczkowski, K.A. (Kenneth A.), Leenders, G.J.H.L. (Geert), Kwast, Th.H. (Theo) van der, Grignon, D.J. (David J.), Evans, A.J. (Andrew J.), Kristiansen, G. (Glen), Kweldam, C.F. (Charlotte), Litjens, G. (Geert), McKenney, J.K. (Jesse K.), Melamed, J. (Jonathan), Mottet, N. (Nicolas), Paner, G.P. (Gladell P.), Samaratunga, H. (Hemamali), Schoots, I.G. (Ivo), Simko, J. (Jeff), Tsuzuki, T. (Toyonori), Varma, M. (Murali), Warren, A.Y. (Anne Y.), Wheeler, T.M. (Thomas), Williamson, S.R. (Sean R.), and Iczkowski, K.A. (Kenneth A.)
- Abstract
Five years after the last prostatic carcinoma grading consensus conference of the International Society of Urological Pathology (ISUP), accrual of new data and modification of clinical practice require an update of current pathologic grading guidelines. This manuscript summarizes the proceedings of the ISUP consensus meeting for grading of prostatic carcinoma held in September 2019, in Nice, France. Topics brought to consensus included the following: (1) approaches to reporting of Gleason patterns 4 and 5 quantities, and minor/tertiary patterns, (2) an agreement to report the presence of invasive cribriform carcinoma, (3) an agreement to incorporate intraductal carcinoma into grading, and (4) individual versus aggregate grading of systematic and multiparametric magnetic resonance imaging-targeted biopsies. Finally, developments in the field of artificial intelligence in the grading of prostatic carcinoma and future research perspectives were discussed.
- Published
- 2020
- Full Text
- View/download PDF
4. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
- Author
-
Mottet, N. (Nicolas), Bellmunt, J. (Joaquim), Bolla, M. (Michel), Briers, E. (Erik), Cumberbatch, M.G. (Marcus G.), Santis, M. (Maria) de, Fossati, N. (Nicola), Gross, T. (Tobias), Henry, A.M. (Ann M.), Joniau, S. (Steven), Lam, T.B. (Thomas B.), Mason, M.D. (Malcolm), Matveev, V. (Vsevolod), Moldovan, P.C. (Paul C.), Bergh, R.C.N. (Roderick) van den, van den Broeck, T. (Thomas), Poel, H.G. (Henk) van der, Kwast, Th.H. (Theo) van der, Rouvière, O. (Olivier), Schoots, I.G. (Ivo), Wiegel, T. (Thomas), Cornford, P. (Philip), Mottet, N. (Nicolas), Bellmunt, J. (Joaquim), Bolla, M. (Michel), Briers, E. (Erik), Cumberbatch, M.G. (Marcus G.), Santis, M. (Maria) de, Fossati, N. (Nicola), Gross, T. (Tobias), Henry, A.M. (Ann M.), Joniau, S. (Steven), Lam, T.B. (Thomas B.), Mason, M.D. (Malcolm), Matveev, V. (Vsevolod), Moldovan, P.C. (Paul C.), Bergh, R.C.N. (Roderick) van den, van den Broeck, T. (Thomas), Poel, H.G. (Henk) van der, Kwast, Th.H. (Theo) van der, Rouvière, O. (Olivier), Schoots, I.G. (Ivo), Wiegel, T. (Thomas), and Cornford, P. (Philip)
- Abstract
Objective: To present a summary of the 2016 version of the European Association of Urology (EAU) - European Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric Oncology (SIOG) Guidelines on screening, diagnosis, and local treatment with curative intent of clinically localised prostate cancer (PCa). Evidence acquisition: The working panel performed a literature review of the new data (2013-2015). The guidelines were updated and the levels of evidence and/or grades of recommendation were added based on a systematic review of the evidence. Evidence synthesis: . BRCA2 mutations have been added as risk factors for early and aggressive disease. In addition to the Gleason score, the five-tier 2014 International Society of Urological Pathology grading system should now be provided. Systematic screening is still not recommended. Instead, an individual risk-adapted strategy following a detailed discussion and taking into account the patient's wishes and life expectancy must be considered. An early prostate-specific antigen test, the use of a risk calculator, or one of the promising biomarker tools are being investigated and might be able to limit the overdetection of insignificant PCa. Breaking the link between diagnosis and treatment may lower the overtreatment risk. Multiparametric magnetic resonance imaging
- Published
- 2017
- Full Text
- View/download PDF
5. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy?
- Author
-
Moldovan, P.C. (Paul C.), van den Broeck, T. (Thomas), Sylvester, R. (Richard), Marconi, L. (Lorenzo), Bellmunt, J. (Joaquim), Bergh, R.C.N. (Roderick) van den, Bolla, M. (Michel), Briers, E. (Erik), Cumberbatch, M.G. (Marcus G.), Fossati, N. (Nicola), Gross, T. (Tobias), Henry, A.M. (Ann M.), Joniau, S. (Steven), Kwast, Th.H. (Theo) van der, Matveev, V. (Vsevolod), Poel, H.G. (Henk) van der, Santis, M. (Maria) de, Schoots, I.G. (Ivo), Wiegel, T. (Thomas), Yuan, C.Y. (Cathy Yuhong), Cornford, P. (Philip), Mottet, N. (Nicolas), Lam, T.B. (Thomas B.), Rouvière, O. (Olivier), Moldovan, P.C. (Paul C.), van den Broeck, T. (Thomas), Sylvester, R. (Richard), Marconi, L. (Lorenzo), Bellmunt, J. (Joaquim), Bergh, R.C.N. (Roderick) van den, Bolla, M. (Michel), Briers, E. (Erik), Cumberbatch, M.G. (Marcus G.), Fossati, N. (Nicola), Gross, T. (Tobias), Henry, A.M. (Ann M.), Joniau, S. (Steven), Kwast, Th.H. (Theo) van der, Matveev, V. (Vsevolod), Poel, H.G. (Henk) van der, Santis, M. (Maria) de, Schoots, I.G. (Ivo), Wiegel, T. (Thomas), Yuan, C.Y. (Cathy Yuhong), Cornford, P. (Philip), Mottet, N. (Nicolas), Lam, T.B. (Thomas B.), and Rouvière, O. (Olivier)
- Abstract
Context: It remains unclear whether patients with a suspicion of prostate cancer (PCa) and negative multiparametric magnetic resonance imaging (mpMRI) can safely obviate prostate biopsy. Objective: To systematically review the literature assessing the negative predictive value (NPV) of mpMRI in patients with a suspicion of PCa. Evidence acquisition: The Embase, Medline, and Cochrane databases were searched up to February 2016. Studies reporting prebiopsy mpMRI results using transrectal or transperineal biopsy as a reference standard were included. We further selected for meta-analysis studies with at least 10-core biopsies as the reference standard, mpMRI comprising at least T2-weighted and diffusion-weighted imaging, positive mpMRI defined as a Prostate Imaging Reporting Data System/Likert score of ≥3/5 or ≥4/5, and results reported at patient level for the detection of overall PCa or clinically significant PCa (csPCa) defined as Gleason ≥7 cancer. Evidence synthesis: A total of 48 studies (9613 patients) were eligible for inclusion. At patient level, the median prevalence was 50.4% (interquartile range [IQR], 36.4-57.7%) for overall cancer and 32.9% (IQR, 28.1-37.2%) for csPCa. The median mpMRI NPV was 82.4% (IQR, 69.0-92.4%) for overall cancer and 88.1% (IQR, 85.7-92.3) for csPCa. NPV significantly decreased when cancer prevalence increased, for overall cancer (r = -0.64, p <. 0.0001) and csPCa (r = -0.75, p = 0.032). Eight studies fulfilled the inclusion criteria for meta-analysis. Seven reported results for overall PCa. When the overall PCa prevalence increased from 30% to 60%, the combined NPV estimates decreased from 88% (95% confidence interval [95% CI], 77-99%) to 67% (95% CI, 56-79%) for a cut-off score of 3/5. Only one study selected for meta-analysis reported results for Gleason ≥7 cancers, with a positive biopsy rate of 29.3%. The corresponding NPV for a cut-off score of ≥3/5 was 87.9%. Conclusions: The NPV of mpMRI varied greatly depending on study des
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.